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RESEARCH ARTICLE
Modulating Myosin Restores Muscle
Function in a Mouse Model
of Nemaline Myopathy
Johan Lindqvist, PhD,1 Yotam Levy, BSc,2 Alisha Pati-Alam, BSc,2
Edna C. Hardeman, PhD,3 Paul Gregorevic, PhD,4,5,6,7 and Julien Ochala, PhD2
Objective: Nemaline myopathy, one of the most common congenital myopathies, is associated with mutations in var-
ious genes including ACTA1. This disease is also characterized by various forms/degrees of muscle weakness, with
most cases being severe and resulting in death in infancy. Recent findings have provided valuable insight into the
underlying pathophysiological mechanisms. Mutations in ACTA1 directly disrupt binding interactions between actin
and myosin, and consequently the intrinsic force-generating capacity of muscle fibers. ACTA1 mutations are also
associated with variations in myofiber size, the mechanisms of which have been unclear. In the present study, we
sought to test the hypotheses that the compromised functional and morphological attributes of skeletal muscles
bearing ACTA1 mutations (1) would be directly due to the inefficient actomyosin complex and (2) could be restored
by manipulating myosin expression.
Methods: We used a knockin mouse model expressing the ACTA1 His40Tyr actin mutation found in human patients.
We then performed in vivo intramuscular injections of recombinant adeno-associated viral vectors harboring a myosin
transgene known to facilitate muscle contraction.
Results: We observed that in the presence of the transgene, the intrinsic force-generating capacity was restored and
myofiber size was normal.
Interpretation: This demonstrates a direct link between disrupted attachment of myosin molecules to actin mono-
mers and muscle fiber atrophy. These data also suggest that further therapeutic interventions should primarily target
myosin dysfunction to alleviate the pathology of ACTA1-related nemaline myopathy.
ANN NEUROL 2016;00:000–000
Nemaline myopathy is one of the most commonforms of congenital myopathy, with a prevalence
that differs between studies (overall <20% of all congenital
myopathies).1–3 Seven genes related to this disease encode
proteins involved in muscle contraction: ACTA1, NEB,
TPM3, TPM2, CFL2, TNNT1, and LMOD3.1,4,5
KBTBD13, KLHL40, and KLHL41 genes have also been
associated with nemaline myopathy but encode proteins con-
tributing to transcriptional regulation and degradation.1
ACTA1 mutations are often missense, changing 1
DNA nucleotide and leading to the replacement of 1
amino acid in the skeletal muscle a-actin protein. For
most cases, these subtle substitutions induce severe frailty
and early mortality.4 Nevertheless, various degrees of
limb, masticatory, and respiratory muscle weakness exist.4
Recent studies using human biopsy tissue and mouse
models have helped to identify some of the cellular and
molecular events that underlie muscle weakness.6–8
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Mutations in ACTA1 often produce actin mutants that
behave as “poison proteins” and modify the binding
interaction between myosin and actin filaments. This dis-
ruption of interaction between myosin and actin mono-
mers diminishes the establishment of cross-bridges in the
strong binding state, thus preventing optimal force-
generating capacity at the level of the myofiber.6–8
Despite these crucial advances in our understanding
of the pathophysiology of ACTA1-related nemaline
myopathy, to date, no cure exists. One reason may lie in
the underappreciation of muscle fiber smallness as
another major contributor of weakness associated with
ACTA1 mutations.4 This variation in myofiber size is
defined, in most patients, by a significant atrophy or
hypotrophy of type I muscle cells.4 As the mechanisms
that contribute to this have not been elucidated, we
sought to investigate this aspect of disease by using a
knockin transgenic mouse model expressing a single resi-
due substitution in skeletal muscle a-actin (His40Tyr), as
a model of the human condition.7,9 The majority of
myofibers (type I as well as type II) from this animal
model are atrophic or hypotrophic.9
We initially hypothesized that the defective myosin
binding to actin filaments and subsequent aberrant
intrinsic force-generating capacity observed in the pres-
ence of His40Tyr would directly limit the force to be
sensed, altering mechanosensitive pathways responsible
for protein turnover, promoting myofiber atrophy or
hypotrophy, and ultimately resulting in severe weakness
and early death (60% of the mice die by 13 weeks of
age).7,10 To test this hypothesis, we attempted to restore
the actomyosin interface in the transgenic mouse model
by directly modulating the myosin light chains (MyLCs).
Each myosin molecule is composed of 2 regulatory and
2 essential/alkali MyLCs.11 Essential/alkali MyLCs have
C-terminal regions involved in the coupling of adenosine
triphosphate (ATP) hydrolysis/myosin arm rotation and
N-terminal domains capable of directly interacting with
actin.11 Thus, different MyLC isoforms with distinct
amino acids in their N- or C-termini are able to promote
or limit force production. For instance, MyLC1a/emb,
which is encoded by the MYL4 gene and only present in
the heart and skeletal muscles of embryos, increases the
force-generating capacity of myosin molecules.11 From
that, we hypothesized that inducing expression of
MyLC1a/emb in mature skeletal myofibers via transgene
delivery (with recombinant adeno-associated virus
[rAAV] vectors containing the MYL4 gene) would (1)
improve the interactions between myosin and actin fila-
ments in wild-type mice, (2) restore the contractile func-
tion in the knockin transgenic mouse model, and (3)
prevent atrophy or hypotrophy by ameliorating the
mechanosensitive pathways responsible for protein
turnover.
We found that vector-mediated expression of
MYL4 significantly ameliorated the atrophy and associ-
ated deficiencies in contractile performance of muscle
fibers in transgenic mice. By using MyLC1a/emb, we did
not intend to directly correct for the His40Tyr mutation,
but rather to compensate for it by specifically improving
myosin cross-bridge function. Thus, our findings suggest
that MYL4-directed interventions could offer promising
therapeutic potential for the treatment of neuromuscular
disorders where an impaired myosin binding is observed.
Materials and Methods
Animals
Six wild-type male mice as well as 6 age- and gender-matched
transgenic mice expressing the His40Tyr amino acid substitu-
tion in skeletal a-actin were included in the analyses. For a
complete description of the mice, please see Nguyen et al.9
Production of rAAV Vectors (rAAV6)
A cDNA construct encoding myosin light chain 4 (MYL4,
GenScript) was cloned into an AAV expression plasmid consist-
ing of a cytomegalovirus promoter/enhancer and an SV40 poly-
A region flanked by AAV2 terminal repeats using standard
cloning techniques. Transfection of these plasmids with the
pDGM6 packaging plasmid into HEK293 cells generated type
6 pseudotyped viral vectors that were harvested and purified as
described previously.12 Briefly, HEK293 cells were plated at a
density of 3.2 to 3.8 3 106 cells on a 10cm culture dish, 8 to
16 hours prior to transfection with 10lg of a vector-genome–
containing plasmid and 20lg of the packaging/helper plasmid
pDGM6, by means of the calcium phosphate precipitate
method to generate pseudotype 6 vectors. Seventy-two hours
after transfection, the media and cells were collected and
homogenized through a microfluidizer (Microfluidics, West-
wood, MA) prior to 0.22lm clarification (Millipore, Billerica,
MA). The vector was purified from the clarified lysate by affin-
ity chromatography over a HiTrap heparin column (GE Health-
care, Little Chalfont, UK), and ultracentrifuged overnight prior
to resuspension in sterile physiological Ringer solution. The
purified vector preparation was titered with a customized
sequence-specific quantitative polymerase chain reaction–based
reaction (Applied Biosystems, Foster City, CA) as described
previously.13
In Vivo Intramuscular Injections
Four-week-old mice (5 wild-type and 6 transgenic males) were
deeply anesthetized with isoflurane, and 1 3 1010 vector
genomes of rAAV6 containing the MYL4 gene (referred to as
rAAV6:MYL4) were injected in 30ll of Hank balanced salt
solution directly into the anterior compartment of the hind-
limb, which is occupied by the tibialis anterior muscle. Control
injections of the contralateral limb used a vector lacking a func-
tional gene (referred to as rAAV6:MCS). Four weeks after the
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injections, animals were killed by cervical dislocation under
deep isoflurane sedation and tibialis anterior muscles were dis-
sected. All procedures involving animal care, welfare, and han-
dling were performed according to institutional guidelines and
were reviewed and approved by the Uppsala Local Ethical
Committee on Animal Research.
Muscle Dissection and Preparation
Upon surgical excision, harvested tibialis anterior muscles were
separated into 2 portions. One piece was directly frozen in liq-
uid nitrogen-chilled propane and stored at 2808C. The other
piece was placed in relaxing solution at 48C. Bundles of
approximately 50 fibers were dissected free and then tied with
surgical silk to glass capillary tubes at just taught lengths. Pre-
pared muscle bundles were subsequently treated with skinning
solution (relaxing solution containing glycerol; 50:50 vol/vol)
for 24 hours at 48C, after which they were transferred to
2208C. In addition, the muscle bundles were treated with
sucrose, a cryoprotectant, within 1 to 2 weeks for long-term
storage.14 They were detached from the capillary tubes and
snap frozen in liquid nitrogen-chilled propane and stored at
2808C.
Functional Measurements
Bundles of prepared muscle fibers were desucrosed and trans-
ferred to a relaxing solution, and single fibers were dissected.
To measure the functional properties, myofibers 1 to 2mm long
were affixed between connectors leading to a force transducer
(model 400A; Aurora Scientific, Aurora, Ontario, Canada) and
a lever arm system (model 308B, Aurora Scientific).15,16 The 2
extremities of the fiber segment were tightly attached to the
connectors as previously described.15 The apparatus was
mounted on the stage of an inverted microscope (model IX70;
Olympus, Tokyo, Japan). The sarcomere length was set to 2.50
to 2.60lm (optimal mouse sarcomere length where the force
production is the highest) and controlled during the experiment
using a high-speed video analysis system (model 901A HVSL,
Aurora Scientific). The diameter of the muscle fiber segment
mounted between the connectors was measured through a
microscope at a magnification of 3320 with an image analysis
system prior to the mechanical experiments. Myofiber depth
was measured by recording the vertical displacement of the
microscope nosepiece while focusing on the top and bottom
surfaces of the fiber. The focusing control of the microscope
was used as a micrometer. Muscle fiber cross-sectional area
(CSA) was calculated from the diameter and depth, assuming
an elliptical circumference, and was corrected for the 20% swel-
ling that is known to occur during skinning.15 Diameter and
depth were measured at 3 different locations along the length
of each fiber segment, and the mean was considered representa-
tive of cell dimensions. As previously described in detail,17–19
mechanical experiments were conducted at 158C and included
force measurements (normalized to CSA) after various length
steps at saturating [Ca21] (pCa 5 4.50). Step changes in fiber
length were imposed and allowed stiffness measurements
(releases of 0.15, 0.3, and 0.5% of fiber length and stretches of
the same amplitudes). Stiffness was defined as the slope of the
linear regression of the relationship between the peak force
response and the length change.
Relaxing and activating solutions contained (in millimo-
lars) 4 Mg-ATP, 1 free Mg21, 20 imidazole, 7 ethyleneglycolte-
traacetic acid (EGTA), 14.5 creatine phosphate, and KCl to
adjust the ionic strength to 180mM and pH to 7.0. The preac-
tivating solution was identical to the relaxing solution except
that the EGTA concentration was reduced to 0.5mM. The con-
centrations of free Ca21 were 1029M (relaxing and preactivat-
ing solutions) and 1024.50M (activating solution), expressed as
pCa (ie, 2log10 [Ca21]). The rigor activating solution was
similar to the regular activating solution except that MgATP
and creatine phosphate were absent.
After the functional measurements, each myofiber was
placed in urea buffer (120g urea, 38g thiourea, 70ml H20, 25g
mixed bed resin, 2.89g dithiothreitol, 1.51g Trizma base, 7.5g
sodium dodecyl sulfate [SDS], 0.004% bromophenol blue) in
a plastic microcentrifuge tube and stored at 2808C. The myo-
sin heavy chain (MyHC) isoform composition was subse-
quently determined by 6% SDS–polyacrylamide gel
electrophoresis.15,16 The acrylamide concentration was 4%
(wt/vol) in the stacking gel and 6% in the running gel, and
the gel matrix included 30% glycerol. Sample loads were kept
small (equivalent to approximately 0.05mm of fiber segment)
to improve the resolution of the MyHC bands (types I, IIa,
IIx, and IIb). Electrophoresis was performed at 120V for 24
hours with a Tris–glycine electrode buffer (pH 8.3) at 158C
(SE 600 vertical slab gel unit; Hoefer Scientific Instruments,
San Francisco, CA). The gels were silver-stained and subse-
quently scanned in a soft laser densitometer (Molecular
Dynamics, Sunnyvale, CA) with a high spatial resolution
(50lm pixel spacing) and 4,096 optical density levels. It
should be mentioned that as no significant differences were
seen between the various MyHC isoforms, all the functional
data were deemed eligible for pooling together.
Cytochemistry and Immunocytochemistry
Ten-micrometer cross-sections were cut perpendicular to the
longitudinal axis of the muscle fibers with a cryostat (2800 Fri-
gocut E; Reichert-Jung, Vienna, Austria) for determination of
morphological characteristics with standard staining protocols
and of MyLC1a/emb expression.
Primary antibody against MyLC1a/emb from rabbit was
diluted 1:100,20 and antirabbit secondary antibody (1:500 dilu-
tion) conjugated with Alexa Flour 488 was detected by fluores-
cence microscopy using a Zeiss (Oberkochen, Germany) LSM
510 Meta (PlanNeofluar 320/0.5 objective). In addition, cross-
sections were processed using standard histological and histo-
chemical procedures. Pictures were captured with a microscope-
mounted camera (DPII camera; Olympus), and calculations of
fiber size were determined using imaging software (Compix
Simple PCI 6; Compix, Irvine, CA).
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FIGURE 1: Tibialis anterior muscles of transgenic mice exhibit
myofiber atrophy at week 8. This figure displays representa-
tive muscle cross-sections taken at different time points and
stained with hematoxylin and eosin. These sections did not
exhibit any major cores or vacuoles but display minor arti-
facts of cryodamage during processing. Values in the graphs
are mean 6 standard error of the mean. *Statistically
significant at p < 0.05. The scale bar represents 50lm. CSA
5 cross-sectional area. [Color figure can be viewed in the
online issue, which is available at www.annalsofneurology.
org.]
FIGURE 2: Incorporation of the transgene in wild-type mice
improves the myofiber function. (A) Typical muscle cross-
sections from the atrium or tibialis anterior muscles from
wild-type animals. The tibialis anterior muscles were injected
with 1 3 1010 vector genomes of rAAV6 containing either
the MYL4 gene (referred to as MYL4) or a vector lacking a
functional gene (referred to as MCS). These cross-sections
were stained for MyLC1a/emb. The scale bar represents 50lm.
(B–E) B, D, and E are graphs depicting the myofiber mechan-
ics, whereas C summarizes the myosin to actin content ratio
in these myofibers. Values in the graphs are mean 6 standard
error of the mean. *Statistically significant at p < 0.05. [Color
figure can be viewed in the online issue, which is available at
www.annalsofneurology.org.]
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Immunoblotting
Markers of potentially activated signaling pathways were eval-
uated using Western blots. Four micrograms of total protein
were loaded per lane into the wells of a 4% (wt/vol) acrylamide
stacking gel with 12% (wt/vol) running gel; the gel matrix
included 10% glycerol. Electrophoresis was performed at 120V
for approximately 90 minutes, and the gels were immediately
transferred to polyvinylidene fluoride membranes (Immobilon
FL, Millipore). Membranes were blocked with 2% ECL Prime
(GE Healthcare) blocking agent for 1 hour and then incubated
with mTOR (#2972; Cell Signaling Technology, Danvers,
MA), p-mTOR (#2974, Cell Signaling Technology), PI3K
(#4257, Cell Signaling Technology), p-Akt (#9271, Cell Sig-
naling Technology), and Akt (#9272, Cell Signaling Technol-
ogy) primary antibodies. Primary antibodies against a-actinin
(A7732; Sigma-Aldrich, St Louis, MO) were used for normal-
ization. All primary antibodies were raised in rabbit except for
a-actinin, which was raised in mouse. After incubation with
secondary antibodies conjugated with horseradish peroxidase
against rabbit (NA934, Amersham GE Healthcare) or rat
(NA931, Amersham GE Healthcare), blots were developed
with ECL Prime detection kit according to the manufacturer’s
instruction (Amersham GE Healthcare). The immunoblots
were sequentially quantified using the chemiluminescence set-
ting in an imaging system (Odyssey Fc Infrared Imaging Sys-
tem; LI-COR, Lincoln, NE).
Statistical Analysis
Data are reported as means 6 standard error of the mean.
Sigma Stat software (Jandel Scientific, San Rafael, CA) and
Excel (Microsoft, Redmond, WA) were used to generate
descriptive statistics. Differences between the groups were deter-
mined by 1-way or 2-way analyses of variance depending on
the data (p-value set at 0.05).
Results and Discussion
Myofiber Atrophy Appeared at 8 Weeks of Age
in Transgenic Mice
To determine whether muscle cells were atrophic or
hypotrophic as a consequence of ACTA1 mutation, we
evaluated the CSA of fibers at different age points in
transgenic mice (2 days, 14 days, 4 weeks, 8 weeks, and
12 weeks after birth). Smaller fibers were observed
toward the end of the episode of postnatal maturation
(ie, 8 and 12 weeks, p < 0.05; Fig 1), which favors
atrophic mechanisms rather than hypotrophy. These
could originate from decreased protein synthesis or from
increased protein degradation. Time-resolved analyses in
humans are warranted to determine whether this holds
FIGURE 3: The myosin transgene alleviates the myofiber
dysfunction in transgenic mice. A, C, and D relate to the
myofiber contractile function in tibialis anterior muscles that
were injected with 1 3 1010 vector genomes of rAAV6
containing either the MYL4 gene (referred to as MYL4) or a
vector lacking a functional gene (referred to as MCS),
whereas C reports the myosin to actin content ratio in the
myofibers. Values in the graphs are mean 6 standard error
of the mean. *Statistically significant at p < 0.05. [Color
figure can be viewed in the online issue, which is available
at www.annalsofneurology.org.]
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true for patients or whether impaired processes of muscle
growth occur.
Having identified a time course for the develop-
ment of muscle fiber atrophy associated with ACTA1
mutation, we sought to investigate whether features of
atrophy could be ameliorated by altering actin–myosin
interaction. For subsequent experiments, we chose to use
4-week old wild-type and transgenic mice (just before
the atrophy onset) that were sampled for examination at
8 weeks of age.
rAAV6:MYL4 Hyperactivated Myosin Molecules
in Wild-Type Mice
Recombinant AAV vectors have been demonstrated to
achieve highly efficient and long-lasting transduction of
mammalian skeletal musculature.21 We used rAAV6 vec-
tors to transduce the muscles of mice with transgene
constructs harboring MYL4. As shown in Figure 2, in
wild-type mice, injections of rAAV6:MYL4 elicited
strong expression of MyLC1a/emb, as detected by immu-
nofluorescent labeling. Treatment of muscles with
rAAV6:MYL4 led to a marked (50%) increase in the
steady-state isometric maximal force-producing capacity
of myofibers when compared with muscles receiving the
rAAV6:MCS control vector (p < 0.05). Such increase
may originate from either a greater amount of myosin
cross-bridges in the strong binding state and/or a higher
force per individual actomyosin interaction. To distin-
guish between these two possibilities, we performed stiff-
ness measurements on isolated muscle fiber segments. As
active and rigor stiffness were both greater with
rAAV6:MYL4 when compared with rAAV6:MCS (p <
0.05), and as the myosin to actin content ratio was not
affected, we attributed the increased force production to
a greater strain per individual myosin cross-bridge, which
may be due to a change in the rigidity of the neck region
of the myosin motor.22
rAAV6:MYL4 Restored the Intrinsic Force-
Generating Capacity and Myofiber Size in
Transgenic Mice
Consistent with the observed increases in force-
producing capacity achieved in wild-type mice, adminis-
tration of rAAV6:MYL4 to the muscles of ACTA1
FIGURE 4: The myosin transgene restores muscle mass in
transgenic mice. (A) Typical muscle cross-sections from the
tibialis anterior muscles from transgenic mice. The tibialis
anterior muscles were injected with 1 3 1010 vector
genomes of rAAV6 containing either the MYL4 gene
(referred to as MYL4) or a vector lacking a functional gene
(referred to as MCS) and were stained with Gomori tri-
chrome (GT), succinic dehydrogenase (SDH), or cytochrome
oxidase (COX). The scale bar represents 50lm. (B) The mus-
cle weights. (C) Myofiber cross-sectional areas (CSA) are
classified according to their oxidative capacity (LO 5 low;
IO 5 intermediate; HO 5 high). (D) The proportion of myo-
fibers having LO, IO, or HO. Values in the graphs are mean
6 standard error of the mean. *Statistically significant at
p < 0.05. [Color figure can be viewed in the online issue,
which is available at www.annalsofneurology.org.]
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mutant mice also improved the steady-state isometric
maximal force production, and active and rigor stiffness
of myofibers when compared with muscles receiving
rAAV6:MCS (p < 0.05; Fig 3). Moreover, we noticed
that the presence of MyLC1a/emb stimulated an increase
in muscle weight and myofiber CSA (p < 0.05; Fig 4B,
C) without any alteration in the proportional composi-
tion of MyHC isoforms/oxidative capacity (see Fig 4D).
The regulation of muscle fiber size is influenced by the
balance between rates of protein degradation and synthe-
sis.23 Hence, to gain insight into the underlying causes
of the increased CSA with rAAV6:MYL4, we sought to
determine whether increased muscle fiber size was a func-
tion of altered signaling via the Akt-mTOR pathway, a
major determinant of protein turnover in muscle.24 We
did not detect differences in the expression or activation
of the upstream element PI3-kinase, or in the activation
of Akt and mTOR as determined from the p-Akt to Akt
and p-mTOR to mTOR ratios (Fig 5). These findings
indicate that other signaling processes, such as other
mechanosensitive pathways, may be responsible for the
increase in myofiber CSA.25 Based on one of our previ-
ous studies on muscle disuse/unloading,26 one may spec-
ulate that, in the presence of His40Tyr, the limited
myosin binding and force production lead to a partial
mechanical silencing that would trigger a complex cas-
cade of molecular events that could activate FoxO and
key muscle-specific E3 ligases such as MuRF-1 and atro-
gin-1/MAFbx. The incorporation of MyLC1a/emb would
be predicted to exert a protective effect upon mechano-
sensing and downstream signaling, which could limit
FoxO-related detrimental effects and thus favor myofiber
growth.
MYL4 as a Potential Future Therapy for
Nemaline Myopathy
Interestingly, the results of the present study also demon-
strate that a molecular intervention designed to promote
expression of MyLC1a/emb in skeletal musculature can
ameliorate features of pathology associated with ACTA1-
related nemaline myopathy. This particular MyLC iso-
form is not commonly expressed in adult skeletal
muscles, but strongly supports myosin cross-bridge bind-
ing to actin filaments. Other molecular interventions
have been proposed as a means to target the contractility
of fibers by sensitizing the troponin–tropomyosin regula-
tory complex to Ca21 or by directly stimulating the
myosin molecules, albeit with limited promise in the
context of nemaline myopathy to date. For instance, a
pharmacological drug (CK-2017357) containing a tropo-
nin activator has been tested.27 By selectively binding to
the troponin complex, CK-2017357 slows the rate of
Ca21 release from troponin C and facilitates myosin acti-
vation. Despite this obvious beneficial effect, CK-
2017357 suffers a major limitation in that it dramatically
slows the rate of Ca21 dissociation from troponin C,
impairing the relaxation process.27 Another compound,
which directly attaches to myosin molecules (omecamtiv
mecarbil, formerly CK-1827452), has successfully shown
inotropic effects.28 However, omecamtiv mecarbil specifi-
cally binds to cardiac myosin molecules, and thus would
not exert efficacy as a therapy for skeletal muscles. By
comparison, the MYL4-based intervention described here
demonstrates a capacity to considerably enhance the
intrinsic contractile capacity of ACTA1-mutant muscle
fibers, and ameliorate fiber atrophy associated with this
disease model. As nemaline myopathy related to defects
in other genes encoding for contractile proteins (ie, NEB,
TPM3, TPM2, CFL2, TNNT1, and LMOD3) is often
characterized by depressed myosin cross-bridge function,
one may suggest that the beneficial compensatory mecha-
nisms related to the incorporation of MyLC1a/emb in
FIGURE 5: The functional beneficial effects of the myosin
transgene do not involve the PI3K-Akt-mTOR signaling in
transgenic mice. This figure shows typical Western blots of
the tibialis anterior muscles from transgenic mice. These
muscles were injected with 1 3 1010 vector genomes of
rAAV6 containing either the MYL4 gene (referred to as
MYL4) or a vector lacking a functional gene (referred to as
MCS). The p-Akt to Akt and p-mTOR to mTOR ratios were
calculated and represented the Akt and mTOR activities,
respectively. Values in the graphs are mean 6 standard
error of the mean. [Color figure can be viewed in the online
issue, which is available at www.annalsofneurology.org.]
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skeletal muscles may be applicable to these other genetic
forms. Accordingly, our intervention strategy represents a
novel and efficacious approach to preventing and/or
treating muscle pathology in the setting of nemaline
myopathy.
Conclusion
The results reported here demonstrate that administra-
tion of recombinant viral vectors carrying a MYL4 con-
struct (1) enhances the interactions between myosin and
actin filaments in wild-type mice, with beneficial effects
for contractile capacity; and (2) prevents muscle atrophy
and enhances the intrinsic force-generating capacity in
ACTA1-mutant mice. Given the potential for rAAV vec-
tors to achieve widespread and long-lasting dissemination
of transgenes to skeletal musculature in vivo, we contend
that further examination of this intervention strategy is
warranted to determine the potential for development as
a novel therapy for nemaline myopathy and other neuro-
muscular disorder-related defects of interaction within
the contractile architecture of muscle fibers. Important
questions to address in future studies include (1) evaluat-
ing the long-term effects of this intervention strategy; (2)
determining whether it is possible to ameliorate disease
features in limb, masticatory, and respiratory muscle via
systemic vector administration; and (3) establishing
whether MYL4-based gene therapy is beneficial in mouse
models of nemaline myopathy carrying other gene defects
such as NEB and TPM3.
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